{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:00Z","timestamp":1792788240758,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Joint Programme for Rare Diseases","award":["EJP RD COFUND-EJP N\u00ba 825575"],"award-info":[{"award-number":["EJP RD COFUND-EJP N\u00ba 825575"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["AC21_2\/00011"],"award-info":[{"award-number":["AC21_2\/00011"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["2019-2.1.7-ERA-NET"],"award-info":[{"award-number":["2019-2.1.7-ERA-NET"]}]},{"DOI":"10.13039\/501100019725","name":"DEBRA Austria","doi-asserted-by":"publisher","award":["DEBRA Austria"],"award-info":[{"award-number":["DEBRA Austria"]}],"id":[{"id":"10.13039\/501100019725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidermolysis bullosa (EB) is a rare genetic disorder that causes extreme skin fragility, chronic pain, and functional impairment, with major psychosocial and economic consequences. Health-related quality of life (HRQoL) data is critical to capture the full burden of EB. Health utilities derived from preference-based generic instruments such as the EQ-5D-5L provide standardized health status utility values that enable cross-disease comparisons and provide input data for cost-utility analyses to inform resource allocation. There is a notable lack of multinational, up-to-date utility data for EB. This cross-sectional study aimed to assess HRQoL in adults with EB across seven European countries (Austria, Bulgaria, Germany, Hungary, Italy, France, and Spain) using the EQ-5D-5L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 328 adults with EB participated in the survey, 61% were female, 37% were between 18 and 30 years old and 46% had dystrophic EB. Based on self-reported symptoms, 58% were classified as severe EB. Pain\/discomfort was the most affected EQ-5D-5L dimension (92% reporting problems; 27% severe or extreme). The mean EQ-5D value (health utility) was 0.63 (SD 0.32), ranging from 0.57 in Spain to 0.71 in Bulgaria. Patients with severe EB reported significantly lower utilities than non-severe cases (0.52 vs. 0.78,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Mean EQ VAS score was 60 (SD 23.2). Compared to general population norms, EB patients in all countries had markedly lower HRQoL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.005), with large effect sizes for the EQ-5D value (Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      \u2009\u2265\u20090.8). Symptomatic burden and functional deterioration were the primary drivers of HRQoL impairments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This multinational study provides the most extensive and current health utility data for adults with EB in Europe. Findings reveal the profound HRQoL impairment in EB, particularly in severe cases. These standardized utility values fill a major evidence gap, supporting their use in health economic evaluations, cross-disease comparisons, and policy development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04299-1","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:55:10Z","timestamp":1773914110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Health-related quality of life in adults with epidermolysis bullosa: a cross-sectional study in seven European countries using EQ-5D-5L"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-9252","authenticated-orcid":false,"given":"Renata","family":"Linertov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"P\u00e9ntek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn","family":"Rodr\u00edguez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bodemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"H\u00fcbl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"El Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Salamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Alonso-Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Stefanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Ramallo-Fari\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Garc\u00eda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BUR-EB Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"1","key":"4299_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Dis Primer. 2020;6(1):78.","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"4299_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol"},{"issue":"1","key":"4299_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4081\/hpr.2013.649","volume":"1","author":"E Dures","year":"2013","unstructured":"Dures E, Rumsey N, Morris M, Gleeson K. A cross sectional, observational survey to assess levels and predictors of psychological wellbeing in adults with epidermolysis bullosa. Health Psychol Res. 2013;1(1):4.","journal-title":"Health Psychol Res"},{"issue":"5","key":"4299_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jaad.2020.03.028","volume":"85","author":"VA Eng","year":"2021","unstructured":"Eng VA, Solis DC, Gorell ES, Choi S, Nazaroff J, Li S, et al. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey. J Am Acad Dermatol. 2021;85(5):1161\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4299_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5021\/ad.2016.28.1.6","volume":"28","author":"IK Jeon","year":"2016","unstructured":"Jeon IK, On HR, Kim SC. Quality of Life and Economic Burden in Recessive Dystrophic Epidermolysis Bullosa. Ann Dermatol. 2016;28(1):6.","journal-title":"Ann Dermatol"},{"key":"4299_CR6","doi-asserted-by":"publisher","unstructured":"Devlin N, Parkin D, Janssen B. Methods for Analysing and Reporting EQ-5D Data [Internet]. Cham: Springer International Publishing; 2020 [cited 2025 Jul 18]. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-030-47622-9","DOI":"10.1007\/978-3-030-47622-9"},{"key":"4299_CR7","doi-asserted-by":"crossref","unstructured":"Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review. Front Public Health [Internet]. 2021 [cited 2025 Jul 3];9. Available from: https:\/\/consensus.app\/papers\/healthrelated-quality-of-life-in-patients-with-different-guan-zhou\/611e3ddd58ae58f9bec390bca9da5f99\/.","DOI":"10.3389\/fpubh.2021.675523"},{"key":"4299_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1017\/S0266462318000557","volume":"34","author":"O Efthymiadou","year":"2018","unstructured":"Efthymiadou O, Mossman J, Kanavos P, Differentiation of health-related quality, of life outcomes between five disease areas: results from an international survey of patients. Int J Technol Assess Health Care. 2018;34:498\u2013506.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"4299_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13023-024-03328-1","volume":"19","author":"I Aranda-Reneo","year":"2024","unstructured":"Aranda-Reneo I, Oliva-Moreno J, Pe\u00f1a-Longobardo LM, Villar-Hern\u00e1ndez \u00c1R, L\u00f3pez-Bastida J. Economic burden and health-related quality of life in patients with epidermolysis bullosa in Spain. Orphanet J Rare Dis. 2024;19(1):352.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4299_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40257-025-00942-y","volume":"26","author":"MP Marinkovich","year":"2025","unstructured":"Marinkovich MP, Paller AS, Guide SV, Gonzalez ME, Lucky AW, Ba\u011fc\u0131 IS, et al. Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. Am J Clin Dermatol. 2025;26(4):623\u201335.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"4299_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2340\/00015555-0947","volume":"90","author":"S Tabolli","year":"2010","unstructured":"Tabolli S, Pagliarello C, Uras C, Di Pietro C, Zambruno G, Castiglia D, et al. Family burden in epidermolysis bullosa is high independent of disease type\/subtype. Acta Derm Venereol. 2010;90(6):607\u201311.","journal-title":"Acta Derm Venereol"},{"issue":"S1","key":"4299_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10198-016-0783-4","volume":"17","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, Serrano-Aguilar P, et al. Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ. 2016;17(S1):31\u201342.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"4299_CR13","first-page":"e70043","volume":"45","author":"J Piercy","year":"2025","unstructured":"Piercy J, Fishman J, Higgins V, Pike J. Impact of Choice of Tariff When Calculating Clinically Meaningful EQ-5D Scores in Metabolic Dysfunction-Associated Steatohepatitis. Liver Int Off J Int Assoc Study Liver. 2025;45(5):e70043.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"6","key":"4299_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig K, von der Graf JM, Greiner W. German Value Set for the EQ-5D-5L. PharmacoEconomics. 2018;36(6):663\u201374.","journal-title":"PharmacoEconomics"},{"issue":"4","key":"4299_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40273-019-00876-4","volume":"38","author":"LF Andrade","year":"2020","unstructured":"Andrade LF, Ludwig K, Goni JMR, Oppe M, de Pouvourville G. A French Value Set for the EQ-5D-5L. PharmacoEconomics. 2020;38(4):413\u201325.","journal-title":"PharmacoEconomics"},{"issue":"9","key":"4299_CR16","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.jval.2020.03.019","volume":"23","author":"F Rencz","year":"2020","unstructured":"Rencz F, Brodszky V, Gul\u00e1csi L, Golicki D, Ruzsa G, Pickard AS, et al. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2020;23(9):1235\u201345.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"4299_CR17","first-page":"114519","volume":"292","author":"AP Finch","year":"2022","unstructured":"Finch AP, Meregaglia M, Ciani O, Roudijk B, Jommi C. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med 1982. 2022;292:114519.","journal-title":"Soc Sci Med 1982"},{"issue":"5","key":"4299_CR18","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","volume":"21","author":"JM Ramos-Go\u00f1i","year":"2018","unstructured":"Ramos-Go\u00f1i JM, Craig BM, Oppe M, Ramallo-Fari\u00f1a Y, Pinto-Prades JL, Luo N, et al. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2018;21(5):596\u2013604.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"12","key":"4299_CR19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40273-022-01194-y","volume":"40","author":"A \u0141aszewska","year":"2022","unstructured":"\u0141aszewska A, Sajjad A, Busschbach J, Simon J, Hakkaart-van Roijen L. Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments. PharmacoEconomics. 2022;40(12):1221\u201334.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"4299_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13690-025-01642-z","volume":"83","author":"S Dewilde","year":"2025","unstructured":"Dewilde S, Tollenaar NH, Phillips G, Paci S, Janssen MF. POPUP: an observational digital study reporting general population norms for the EQ-5D-5-L and HUI-3 in 8 countries. Arch Public Health Arch Belg Sante Publique. 2025;83(1):184.","journal-title":"Arch Public Health Arch Belg Sante Publique"},{"issue":"8","key":"4299_CR21","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10198-020-01225-5","volume":"21","author":"M Encheva","year":"2020","unstructured":"Encheva M, Djambazov S, Vekov T, Golicki D. EQ-5D-5L Bulgarian population norms. Eur J Health Econ HEPAC Health Econ Prev Care. 2020;21(8):1169\u201378.","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"issue":"9","key":"4299_CR22","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s10198-022-01559-2","volume":"24","author":"L Gautier","year":"2023","unstructured":"Gautier L, Azzi J, Saba G, Bonnelye G, de Pouvourville G. Population norms in France with EQ-5D-5L: health states, value indexes, and VAS. Eur J Health Econ HEPAC Health Econ Prev Care. 2023;24(9):1517\u201330.","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"issue":"6","key":"4299_CR23","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10198-024-01755-2","volume":"26","author":"M P\u00e9ntek","year":"2025","unstructured":"P\u00e9ntek M, J\u00e1ger V, Kincses \u00c1, H\u00f6lgyesi \u00c1, Zrubka Z, Baji P, et al. Population norms for the EQ-5D-5L for Hungary: comparison of online surveys and computer assisted personal interviews. Eur J Health Econ. 2025;26(6):1111\u201326.","journal-title":"Eur J Health Econ"},{"key":"4299_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.4324\/9780203771587","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"2013","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. New York: Routledge; 2013. p. 567.","edition":"2"},{"key":"4299_CR25","doi-asserted-by":"crossref","unstructured":"Arias-Merino G, Benito-Lozano J, G\u00f3mez-Martinez M, Villaverde-Hueso A, Linertov\u00e1 R, Alonso-Ferreira V, et al. Health-related quality of life evaluation in epidermolysis bullosa: a scoping review. Br J Dermatol. 2025;ljaf274.","DOI":"10.1186\/s13643-025-02918-9"},{"issue":"24","key":"4299_CR26","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Ba\u011fc\u0131 IS, Agostini B, Chen H, Feeney G, et al. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med. 2022;387(24):2211\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"4299_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bjd\/ljac001","volume":"188","author":"JS Kern","year":"2023","unstructured":"Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188(1):12\u201321.","journal-title":"Br J Dermatol"},{"issue":"10499","key":"4299_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0140-6736(25)00778-0","volume":"406","author":"JY Tang","year":"2025","unstructured":"Tang JY, Marinkovich MP, Wiss K, McCarthy D, Truesdale A, Chiou AS, et al. Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. Lancet Lond Engl. 2025;406(10499):163\u201373.","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"4299_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10198-024-01728-5","volume":"26","author":"\u00c1 Szab\u00f3","year":"2025","unstructured":"Szab\u00f3 \u00c1, Brodszky V, Rencz F, Comparing. EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases. Eur J Health Econ HEPAC Health Econ Prev Care. 2025;26(4):627\u201339.","journal-title":"Eur J Health Econ HEPAC Health Econ Prev Care"},{"issue":"1","key":"4299_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13023-022-02419-1","volume":"17","author":"A Angelis","year":"2022","unstructured":"Angelis A, Mellerio JE, Kanavos P. Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. Orphanet J Rare Dis. 2022;17(1):346.","journal-title":"Orphanet J Rare Dis"},{"key":"4299_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jdin.2020.12.007","volume":"2","author":"CL Rogers","year":"2021","unstructured":"Rogers CL, Gibson M, Kern JS, Martin LK, Robertson SJ, Daniel BS, et al. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB). JAAD Int. 2021;2:134\u201352.","journal-title":"JAAD Int"},{"issue":"3","key":"4299_CR32","doi-asserted-by":"publisher","first-page":"E102","DOI":"10.1097\/SGA.0000000000000530","volume":"43","author":"GE Cassar","year":"2020","unstructured":"Cassar GE, Youssef GJ, Knowles S, Moulding R, Austin DW. Health-Related Quality of Life in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Gastroenterol Nurs Off J Soc Gastroenterol Nurses Assoc. 2020;43(3):E102\u201322.","journal-title":"Gastroenterol Nurs Off J Soc Gastroenterol Nurses Assoc"},{"issue":"10","key":"4299_CR33","first-page":"2433","volume":"24","author":"M Dellenmark-Blom","year":"2015","unstructured":"Dellenmark-Blom M, Chaplin JE, Gatzinsky V, J\u00f6nsson L, Abrahamson K. Health-related quality of life among children, young people and adults with esophageal atresia: a review of the literature and recommendations for future research. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2015;24(10):2433\u201345.","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"issue":"7","key":"4299_CR34","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/jpepsy\/jsaa052","volume":"45","author":"M Pinquart","year":"2020","unstructured":"Pinquart M. Health-Related Quality of Life of Young People With and Without Chronic Conditions. J Pediatr Psychol. 2020;45(7):780\u201392.","journal-title":"J Pediatr Psychol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04299-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04299-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:20:56Z","timestamp":1777339256000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04299-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4299"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04299-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study. Approval for the study was granted by ethics committee in each participating country: Ethics Commission of the Faculty of Psychotherapy Science and the Faculty of Psychology, Sigmund Freud University, Austria; Ethics Committee at the St. Panteleimon Hospital, Plovdiv, Bulgaria; Assitance H\u00f4pitaux Publique de Paris, Bureau de la Protection des Donn\u00e9es, France; Ethics Committee of Albert-Ludwigs-University Freiburg (22-1519-S2), Germany; Hungarian Medical Research Council (BM\/26385-3\/2023), Hungary; Ospedale Pediatrico Bambino Ges\u00f9 Ethics Committee, Italy (protocol n. 3107\/2023); Complejo Hospitalario Universitario de Canarias Ethics Committee, Spain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MEH, ChB and Cristina Has (member of the BUR-EB Study Group) are members of the European Reference Network for Rare Skin Diseases (ERN-Skin). ChB is the coordinator of ERN-Skin. MP is member of the EuroQol Group, the views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the EuroQol Group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors information"}},{"value":"The authors declare no competing interest for this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}